PROK logo

PROK ProKidney Corp.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.04
-0.02 (-1.89%)

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals wi…

Market Cap: $349.70Mwww.prokidney.com

Price

No data yet.

Social Signal Score

57
5d
50
1 mentions
—
30d
63
3 mentions
—
60d
58
5 mentions
—
90d
58
5 mentions
—
news: 5

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 1Sell 1Strong Sell 0
Avg price target$4.67+349.0%
Low $3Median $5High $6
Current Consensus

Revenue

$174.0K
$0.00$76.7K$153.3K$230.0K
Dec 2020Sep 2026

Analyst Estimates

FY2025
$-0.58
$-0.98–$-0.37
5 analysts
FY2026
$-0.74
$-0.82–$-0.66
3 analysts
FY2027
$-0.72
$-1.24–$-0.38
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Bruce Culleton
Sector
Healthcare
Industry
Biotechnology
Employees
231
Beta
1.90
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-4.90
www.prokidney.com